tiprankstipranks
Trending News
More News >

Health Catalyst price target lowered to $6.50 from $7 at Citi

Citi lowered the firm’s price target on Health Catalyst (HCAT) to $6.50 from $7 and keeps a Buy rating on the shares. The firm expects another volatile earnings season for its health tech coverage. Health tech companies should be well-insulated from tariffs and a potential recession, which would lead to less earnings volatility this year versus the broader market, however, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue